Moreover, the current standard of care for early breast cancer is even superior to the treatment received by many patients in the ALTTO study, including neoadjuvant therapy with pertuzumab, adjustment of adjuvant therapy based on pathological response to neoadjuvant therapy (i.e., T-DM1 for patients who do not achieve pathological complete response) and considering extended adjuvant anti-HER2 therapy with neratinib and endocrine therapy for patients with hormone receptor-positive disease. Here, NR4A1 is linked to breast carcinoma.